Who are Methotrexate+Prednisone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Methotrexate + Methylprednisolone, Methotrexate/Hydrocortisone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methotrexate-prednisone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Methotrexate+Prednisone — Competitive Intelligence Brief

Methotrexate+Prednisone (Methotrexate+Prednisone) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite + Corticosteroid combination. Area: Immunology / Rheumatology.

phase 3 Antimetabolite + Corticosteroid combination Dihydrofolate reductase (methotrexate); Glucocorticoid receptor (prednisone) Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Methotrexate+Prednisone (Methotrexate+Prednisone) — University of Parma. Methotrexate inhibits dihydrofolate reductase to suppress cell proliferation and immune activation, while prednisone suppresses inflammatory and immune responses through glucocorticoid receptor binding.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Methotrexate+Prednisone TARGET	Methotrexate+Prednisone	University of Parma	phase 3	Antimetabolite + Corticosteroid combination	Dihydrofolate reductase (methotrexate); Glucocorticoid receptor (prednisone)
Methotrexate + Methylprednisolone	Methotrexate + Methylprednisolone	Université Catholique de Louvain	marketed	Antimetabolite + Corticosteroid combination	Dihydrofolate reductase (methotrexate); Glucocorticoid receptor (methylprednisolone)
Methotrexate/Hydrocortisone	Methotrexate/Hydrocortisone	Dana-Farber Cancer Institute	phase 3	Antimetabolite + Corticosteroid combination	Dihydrofolate reductase (methotrexate); Glucocorticoid receptor (hydrocortisone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite + Corticosteroid combination class)

Dana-Farber Cancer Institute · 1 drug in this class
University of Parma · 1 drug in this class
Université Catholique de Louvain · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methotrexate+Prednisone — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-prednisone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab